APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ornithine-Transcarbamylase Deficiency

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Ornithine-Transcarbamylase Deficiency Industry Growth and Trends Forecast to 2032

26 December 202595 pages

Choose your research edition.

Industry ResearchOrnithine-Transcarbamylase Deficiency Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Ornithine-Transcarbamylase Deficiency Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Ornithine-Transcarbamylase Deficiency Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ornithine-Transcarbamylase Deficiency Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Ornithine-Transcarbamylase Deficiency Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Ornithine-Transcarbamylase Deficiency market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Ornithine-Transcarbamylase Deficiency is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Ornithine-Transcarbamylase Deficiency is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ornithine-Transcarbamylase Deficiency is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Ornithine-Transcarbamylase Deficiency include Lucane Pharma SA, PhaseRx Inc, Promethera Biosciences SA, Selecta Biosciences Inc, Translate Bio Inc, Ultragenyx Pharmaceutical Inc and Unicyte AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Ornithine-Transcarbamylase Deficiency market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Ornithine-Transcarbamylase Deficiency market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Ornithine-Transcarbamylase Deficiency market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Ornithine-Transcarbamylase Deficiency.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Ornithine-Transcarbamylase Deficiency market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Ornithine-Transcarbamylase Deficiency Market by Company

Lucane Pharma SA

PhaseRx Inc

Promethera Biosciences SA

Selecta Biosciences Inc

Translate Bio Inc

Ultragenyx Pharmaceutical Inc

Unicyte AG

Ornithine-Transcarbamylase Deficiency Segment by Type

SHP-641

SEL-313

PRX-OTC

DTX-301

Others

Ornithine-Transcarbamylase Deficiency Segment by Application

Hospital

Clinic

Others

Ornithine-Transcarbamylase Deficiency Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ornithine-Transcarbamylase Deficiency market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ornithine-Transcarbamylase Deficiency and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ornithine-Transcarbamylase Deficiency.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Ornithine-Transcarbamylase Deficiency manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Ornithine-Transcarbamylase Deficiency in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of SHP-641 Table 2. Major Company of SEL-313 Table 3. Major Company of PRX-OTC Table 4. Major Company of DTX-301 Table 5. Major Company of Others Table 6. Global Ornithine-Transcarbamylase Deficiency Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (W Units) Table 8. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Type (2021-2026) Table 9. Global Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (US$ Million) Table 10. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Type (2021-2026) Table 11. Global Ornithine-Transcarbamylase Deficiency Price by Type (2021-2026) & (US$/Unit) Table 12. Global Ornithine-Transcarbamylase Deficiency Sales by Type (2027-2032) & (W Units) Table 13. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Type (2027-2032) Table 14. Global Ornithine-Transcarbamylase Deficiency Sales by Type (2027-2032) & (US$ Million) Table 15. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Type (2027-2032) Table 16. Global Ornithine-Transcarbamylase Deficiency Price by Type (2027-2032) & (US$/Unit) Table 17. North America Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (W Units) Table 18. North America Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (W Units) Table 20. Europe Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (W Units) Table 22. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (W Units) Table 24. Latin America Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (W Units) Table 26. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2026) & (US$ Million) Table 27. Ornithine-Transcarbamylase Deficiency Industry Trends Table 28. Ornithine-Transcarbamylase Deficiency Industry Drivers Table 29. Ornithine-Transcarbamylase Deficiency Industry Opportunities and Challenges Table 30. Ornithine-Transcarbamylase Deficiency Industry Restraints Table 31. Global Ornithine-Transcarbamylase Deficiency Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Company (2021-2026) Table 33. Global Ornithine-Transcarbamylase Deficiency Sales by Company (2021-2026) & (W Units) Table 34. Global Ornithine-Transcarbamylase Deficiency Sales Share by Company (2021-2026) Table 35. Global Ornithine-Transcarbamylase Deficiency Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Ornithine-Transcarbamylase Deficiency Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Ornithine-Transcarbamylase Deficiency Major Company Production Sites and Headquarters Table 38. Global Ornithine-Transcarbamylase Deficiency Company, Product Type & Application Table 39. Global Ornithine-Transcarbamylase Deficiency Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Ornithine-Transcarbamylase Deficiency by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Ornithine-Transcarbamylase Deficiency Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Ornithine-Transcarbamylase Deficiency Sales by Region (2021-2026) & (W Units) Table 44. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Region (2021-2026) Table 45. Global Ornithine-Transcarbamylase Deficiency Sales by Region (2021-2026) & (US$ Million) Table 46. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Region (2021-2026) Table 47. Global Ornithine-Transcarbamylase Deficiency Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Ornithine-Transcarbamylase Deficiency Sales by Region (2027-2032) & (W Units) Table 49. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Region (2027-2032) Table 50. Global Ornithine-Transcarbamylase Deficiency Sales by Region (2027-2032) & (US$ Million) Table 51. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Region (2027-2032) Table 52. Global Ornithine-Transcarbamylase Deficiency Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Ornithine-Transcarbamylase Deficiency Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (W Units) Table 55. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Application (2021-2026) Table 56. Global Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (US$ Million) Table 57. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Application (2021-2026) Table 58. Global Ornithine-Transcarbamylase Deficiency Price by Application (2021-2026) & (US$/Unit) Table 59. Global Ornithine-Transcarbamylase Deficiency Sales by Application (2027-2032) & (W Units) Table 60. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Application (2027-2032) Table 61. Global Ornithine-Transcarbamylase Deficiency Sales by Application (2027-2032) & (US$ Million) Table 62. Global Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Application (2027-2032) Table 63. Global Ornithine-Transcarbamylase Deficiency Price by Application (2027-2032) & (US$/Unit) Table 64. North America Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (W Units) Table 65. North America Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (W Units) Table 67. Europe Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (W Units) Table 69. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (W Units) Table 71. Latin America Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (W Units) Table 73. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2026) & (US$ Million) Table 74. Lucane Pharma SA Company Information Table 75. Lucane Pharma SA Business Overview Table 76. Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Product Portfolio Table 78. Lucane Pharma SA Recent Development Table 79. PhaseRx Inc Company Information Table 80. PhaseRx Inc Business Overview Table 81. PhaseRx Inc Ornithine-Transcarbamylase Deficiency Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. PhaseRx Inc Ornithine-Transcarbamylase Deficiency Product Portfolio Table 83. PhaseRx Inc Recent Development Table 84. Promethera Biosciences SA Company Information Table 85. Promethera Biosciences SA Business Overview Table 86. Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Product Portfolio Table 88. Promethera Biosciences SA Recent Development Table 89. Selecta Biosciences Inc Company Information Table 90. Selecta Biosciences Inc Business Overview Table 91. Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Product Portfolio Table 93. Selecta Biosciences Inc Recent Development Table 94. Translate Bio Inc Company Information Table 95. Translate Bio Inc Business Overview Table 96. Translate Bio Inc Ornithine-Transcarbamylase Deficiency Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Translate Bio Inc Ornithine-Transcarbamylase Deficiency Product Portfolio Table 98. Translate Bio Inc Recent Development Table 99. Ultragenyx Pharmaceutical Inc Company Information Table 100. Ultragenyx Pharmaceutical Inc Business Overview Table 101. Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Product Portfolio Table 103. Ultragenyx Pharmaceutical Inc Recent Development Table 104. Unicyte AG Company Information Table 105. Unicyte AG Business Overview Table 106. Unicyte AG Ornithine-Transcarbamylase Deficiency Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Unicyte AG Ornithine-Transcarbamylase Deficiency Product Portfolio Table 108. Unicyte AG Recent Development Table 109. North America Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 110. North America Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2026) & (W Units) Table 111. North America Ornithine-Transcarbamylase Deficiency Sales Market Share by Country (2021-2026) Table 112. North America Ornithine-Transcarbamylase Deficiency Sales Forecast by Country (2027-2032) & (W Units) Table 113. North America Ornithine-Transcarbamylase Deficiency Sales Market Share Forecast by Country (2027-2032) Table 114. North America Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 115. North America Ornithine-Transcarbamylase Deficiency Market Size by Country (2021-2026) & (US$ Million) Table 116. North America Ornithine-Transcarbamylase Deficiency Market Share by Country (2021-2026) Table 117. North America Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country (2027-2032) & (US$ Million) Table 118. North America Ornithine-Transcarbamylase Deficiency Market Share Forecast by Country (2027-2032) Table 119. Europe Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 120. Europe Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2026) & (W Units) Table 121. Europe Ornithine-Transcarbamylase Deficiency Sales Market Share by Country (2021-2026) Table 122. Europe Ornithine-Transcarbamylase Deficiency Sales Forecast by Country (2027-2032) & (W Units) Table 123. Europe Ornithine-Transcarbamylase Deficiency Sales Market Share Forecast by Country (2027-2032) Table 124. Europe Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. Europe Ornithine-Transcarbamylase Deficiency Market Size by Country (2021-2026) & (US$ Million) Table 126. Europe Ornithine-Transcarbamylase Deficiency Market Share by Country (2021-2026) Table 127. Europe Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. Europe Ornithine-Transcarbamylase Deficiency Market Share Forecast by Country (2027-2032) Table 129. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 130. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2026) & (W Units) Table 131. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Market Share by Country (2021-2026) Table 132. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Forecast by Country (2027-2032) & (W Units) Table 133. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Market Share Forecast by Country (2027-2032) Table 134. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Country (2021-2026) & (US$ Million) Table 136. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Share by Country (2021-2026) Table 137. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Share Forecast by Country (2027-2032) Table 139. Latin America Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 140. Latin America Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2026) & (W Units) Table 141. Latin America Ornithine-Transcarbamylase Deficiency Sales Market Share by Country (2021-2026) Table 142. Latin America Ornithine-Transcarbamylase Deficiency Sales Forecast by Country (2027-2032) & (W Units) Table 143. Latin America Ornithine-Transcarbamylase Deficiency Sales Market Share Forecast by Country (2027-2032) Table 144. Latin America Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Latin America Ornithine-Transcarbamylase Deficiency Market Size by Country (2021-2026) & (US$ Million) Table 146. Latin America Ornithine-Transcarbamylase Deficiency Market Share by Country (2021-2026) Table 147. Latin America Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Latin America Ornithine-Transcarbamylase Deficiency Market Share Forecast by Country (2027-2032) Table 149. Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 150. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2026) & (W Units) Table 151. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Market Share by Country (2021-2026) Table 152. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Forecast by Country (2027-2032) & (W Units) Table 153. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Market Share Forecast by Country (2027-2032) Table 154. Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Size by Country (2021-2026) & (US$ Million) Table 156. Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Share by Country (2021-2026) Table 157. Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Share Forecast by Country (2027-2032) Table 159. Key Raw Materials Table 160. Raw Materials Key Suppliers Table 161. Ornithine-Transcarbamylase Deficiency Distributors List Table 162. Ornithine-Transcarbamylase Deficiency Customers List Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Ornithine-Transcarbamylase Deficiency Image Figure 2. Global Ornithine-Transcarbamylase Deficiency Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ornithine-Transcarbamylase Deficiency Market Size (2021-2032) & (US$ Million) Figure 4. Global Ornithine-Transcarbamylase Deficiency Sales (2021-2032) & (W Units) Figure 5. SHP-641 Image Figure 6. Global SHP-641 Sales YoY Growth (2021-2032) & (W Units) Figure 7. SEL-313 Image Figure 8. Global SEL-313 Sales YoY Growth (2021-2032) & (W Units) Figure 9. PRX-OTC Image Figure 10. Global PRX-OTC Sales YoY Growth (2021-2032) & (W Units) Figure 11. DTX-301 Image Figure 12. Global DTX-301 Sales YoY Growth (2021-2032) & (W Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 15. Global Ornithine-Transcarbamylase Deficiency Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Ornithine-Transcarbamylase Deficiency Market Share by Type 2025 VS 2032 Figure 17. North America Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Type in 2025 Figure 18. North America Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Type in 2025 Figure 19. Europe Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Type in 2025 Figure 20. Europe Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Type in 2025 Figure 23. Latin America Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Ornithine-Transcarbamylase Deficiency Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 35. Global Ornithine-Transcarbamylase Deficiency Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Ornithine-Transcarbamylase Deficiency Market Share by Application 2025 VS 2032 Figure 37. North America Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Application in 2025 Figure 38. North America Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Application in 2025 Figure 39. Europe Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Application in 2025 Figure 40. Europe Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Application in 2025 Figure 43. Latin America Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Market Share in Value by Application in 2025 Figure 47. North America Ornithine-Transcarbamylase Deficiency Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 48. North America Ornithine-Transcarbamylase Deficiency Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Ornithine-Transcarbamylase Deficiency Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Ornithine-Transcarbamylase Deficiency Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Ornithine-Transcarbamylase Deficiency Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 52. Europe Ornithine-Transcarbamylase Deficiency Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Ornithine-Transcarbamylase Deficiency Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Ornithine-Transcarbamylase Deficiency Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 56. Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Ornithine-Transcarbamylase Deficiency Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 60. Latin America Ornithine-Transcarbamylase Deficiency Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Ornithine-Transcarbamylase Deficiency Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Ornithine-Transcarbamylase Deficiency Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 64. Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Ornithine-Transcarbamylase Deficiency Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Ornithine-Transcarbamylase Deficiency Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • SHP-641
  • SEL-313
  • PRX-OTC
  • DTX-301
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Lucane Pharma SA
  • PhaseRx Inc
  • Promethera Biosciences SA
  • Selecta Biosciences Inc
  • Translate Bio Inc
  • Ultragenyx Pharmaceutical Inc
  • Unicyte AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Ornithine-Transcarbamylase Deficiency Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Ornithine-Transcarbamylase Deficiency Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Ornithine-Transcarbamylase Deficiency Market by Type
  6. 1.3.1 SHP-641
  7. 1.3.2 SEL-313
  8. 1.3.3 PRX-OTC
  9. 1.3.4 DTX-301
  10. 1.3.5 Others
  11. 1.4 Global Ornithine-Transcarbamylase Deficiency Market Size by Type
  12. 1.4.1 Global Ornithine-Transcarbamylase Deficiency Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Ornithine-Transcarbamylase Deficiency Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Ornithine-Transcarbamylase Deficiency Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Ornithine-Transcarbamylase Deficiency Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Ornithine-Transcarbamylase Deficiency Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Ornithine-Transcarbamylase Deficiency Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Ornithine-Transcarbamylase Deficiency Industry Trends
  2. 2.2 Ornithine-Transcarbamylase Deficiency Industry Drivers
  3. 2.3 Ornithine-Transcarbamylase Deficiency Industry Opportunities and Challenges
  4. 2.4 Ornithine-Transcarbamylase Deficiency Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Ornithine-Transcarbamylase Deficiency Revenue (2021-2026)
  2. 3.2 Global Top Players by Ornithine-Transcarbamylase Deficiency Sales (2021-2026)
  3. 3.3 Global Top Players by Ornithine-Transcarbamylase Deficiency Price (2021-2026)
  4. 3.4 Global Ornithine-Transcarbamylase Deficiency Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Ornithine-Transcarbamylase Deficiency Major Company Production Sites & Headquarters
  6. 3.6 Global Ornithine-Transcarbamylase Deficiency Company, Product Type & Application
  7. 3.7 Global Ornithine-Transcarbamylase Deficiency Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Ornithine-Transcarbamylase Deficiency Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Ornithine-Transcarbamylase Deficiency Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Ornithine-Transcarbamylase Deficiency Tier 1, Tier 2, and Tier 3
4 Ornithine-Transcarbamylase Deficiency Regional Status and Outlook
  1. 4.1 Global Ornithine-Transcarbamylase Deficiency Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Ornithine-Transcarbamylase Deficiency Historic Market Size by Region
  3. 4.2.1 Global Ornithine-Transcarbamylase Deficiency Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Ornithine-Transcarbamylase Deficiency Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Ornithine-Transcarbamylase Deficiency Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Ornithine-Transcarbamylase Deficiency Forecasted Market Size by Region
  7. 4.3.1 Global Ornithine-Transcarbamylase Deficiency Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Ornithine-Transcarbamylase Deficiency Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Ornithine-Transcarbamylase Deficiency Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Ornithine-Transcarbamylase Deficiency by Application
  1. 5.1 Ornithine-Transcarbamylase Deficiency Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Ornithine-Transcarbamylase Deficiency Market Size by Application
  6. 5.2.1 Global Ornithine-Transcarbamylase Deficiency Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Ornithine-Transcarbamylase Deficiency Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Ornithine-Transcarbamylase Deficiency Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Ornithine-Transcarbamylase Deficiency Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Ornithine-Transcarbamylase Deficiency Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Ornithine-Transcarbamylase Deficiency Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Lucane Pharma SA
  2. 6.1.1 Lucane Pharma SA Company Information
  3. 6.1.2 Lucane Pharma SA Business Overview
  4. 6.1.3 Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Product Portfolio
  6. 6.1.5 Lucane Pharma SA Recent Developments
  7. 6.2 PhaseRx Inc
  8. 6.2.1 PhaseRx Inc Company Information
  9. 6.2.2 PhaseRx Inc Business Overview
  10. 6.2.3 PhaseRx Inc Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 PhaseRx Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
  12. 6.2.5 PhaseRx Inc Recent Developments
  13. 6.3 Promethera Biosciences SA
  14. 6.3.1 Promethera Biosciences SA Company Information
  15. 6.3.2 Promethera Biosciences SA Business Overview
  16. 6.3.3 Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Product Portfolio
  18. 6.3.5 Promethera Biosciences SA Recent Developments
  19. 6.4 Selecta Biosciences Inc
  20. 6.4.1 Selecta Biosciences Inc Company Information
  21. 6.4.2 Selecta Biosciences Inc Business Overview
  22. 6.4.3 Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
  24. 6.4.5 Selecta Biosciences Inc Recent Developments
  25. 6.5 Translate Bio Inc
  26. 6.5.1 Translate Bio Inc Company Information
  27. 6.5.2 Translate Bio Inc Business Overview
  28. 6.5.3 Translate Bio Inc Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Translate Bio Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
  30. 6.5.5 Translate Bio Inc Recent Developments
  31. 6.6 Ultragenyx Pharmaceutical Inc
  32. 6.6.1 Ultragenyx Pharmaceutical Inc Company Information
  33. 6.6.2 Ultragenyx Pharmaceutical Inc Business Overview
  34. 6.6.3 Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
  36. 6.6.5 Ultragenyx Pharmaceutical Inc Recent Developments
  37. 6.7 Unicyte AG
  38. 6.7.1 Unicyte AG Company Information
  39. 6.7.2 Unicyte AG Business Overview
  40. 6.7.3 Unicyte AG Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Unicyte AG Ornithine-Transcarbamylase Deficiency Product Portfolio
  42. 6.7.5 Unicyte AG Recent Developments
7 North America by Country
  1. 7.1 North America Ornithine-Transcarbamylase Deficiency Sales by Country
  2. 7.1.1 North America Ornithine-Transcarbamylase Deficiency Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2026)
  4. 7.1.3 North America Ornithine-Transcarbamylase Deficiency Sales Forecast by Country (2027-2032)
  5. 7.2 North America Ornithine-Transcarbamylase Deficiency Market Size by Country
  6. 7.2.1 North America Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Ornithine-Transcarbamylase Deficiency Market Size by Country (2021-2026)
  8. 7.2.3 North America Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Ornithine-Transcarbamylase Deficiency Sales by Country
  2. 8.1.1 Europe Ornithine-Transcarbamylase Deficiency Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2026)
  4. 8.1.3 Europe Ornithine-Transcarbamylase Deficiency Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Ornithine-Transcarbamylase Deficiency Market Size by Country
  6. 8.2.1 Europe Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Ornithine-Transcarbamylase Deficiency Market Size by Country (2021-2026)
  8. 8.2.3 Europe Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales by Country
  2. 9.1.1 Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Ornithine-Transcarbamylase Deficiency Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Country
  6. 9.2.1 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Ornithine-Transcarbamylase Deficiency Sales by Country
  2. 10.1.1 South America Ornithine-Transcarbamylase Deficiency Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2026)
  4. 10.1.3 South America Ornithine-Transcarbamylase Deficiency Sales Forecast by Country (2027-2032)
  5. 10.2 South America Ornithine-Transcarbamylase Deficiency Market Size by Country
  6. 10.2.1 South America Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Ornithine-Transcarbamylase Deficiency Market Size by Country (2021-2026)
  8. 10.2.3 South America Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales by Country
  2. 11.1.1 Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Size by Country
  6. 11.2.1 Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Ornithine-Transcarbamylase Deficiency Value Chain Analysis
  2. 12.1.1 Ornithine-Transcarbamylase Deficiency Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Ornithine-Transcarbamylase Deficiency Production Mode & Process
  7. 12.2 Ornithine-Transcarbamylase Deficiency Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Ornithine-Transcarbamylase Deficiency Distributors
  10. 12.2.3 Ornithine-Transcarbamylase Deficiency Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst